Jotbody (HK) Limited, established in 2020, is a biotech company specializing in nanobodies and extracellular vesicle (EV) research. We are driven by a team of passionate scientists and experienced board members. Located in Hong Kong and Shenzhen, we have access to thriving biotech ecosystems and state-of-the-art facilities.
Our vision is to make high-quality research and development widely accessible, benefiting patients and healthcare providers globally. We take pride in our comprehensive nanobody CRO services, which support scientific research. Additionally, we offer top-notch, timely, and cost-effective nanobody-based research reagents to the global scientific community.
Moreover, our expertise extends beyond nanobodies as we possess specialized knowledge in the field of EV therapeutics. As pioneers in this field, we use advanced technologies and platforms to drive EV research and practical applications. Our expertise includes enhancing EVs with nanobodies, enabling precise and targeted therapeutic delivery. We provide a range of EV solutions, such as loading, surface modification, and validation for effective targeting.
At Jotbody, we are dedicated to advancing nanobodies and EV research, delivering innovative solutions for targeted therapeutic delivery, and contributing to scientific progress.
Jotbody offers an extensive range of high-quality nanobodies from camelids (VHH) and sharks (vNAR). We use advanced technologies to produce the antigens and validate the nanobody through multiple applications and protein samples. These applications include precision medicine, molecular biology, imaging, analytical technique, and plate-based assay.
All our antibodies undergo extensive testing to ensure optimal specificity, sensitivity, and reproducibility, providing you with reliable results every time. Our nanobodies are a unique and powerful tool for detecting and quantifying a wide range of proteins.
If you’re looking for high-quality antibodies that meet the rigorous standards of scientific research, look no further than Jotbody. Browse through our catalog of thoroughly tested primary and secondary antibodies to find the perfect solution for your research needs.
Conventional vertebrate immunoglobulins (Igs) are tetramers of two heavy and two light chains, in which the variable domains of each chain (VH and VL, respectively) assemble to form the antigen-binding site.
In 1993, Hamers-Casterman et al. discovered the presence of heavy-chain-only antibodies in the sera of camelid species. These heavy-chain-only antibodies are composed of two identical heavy chains, each comprising two constant domains (CH2 and CH3), a hinge region, and a variable VHH domain responsible for antigen recognition. Antigen binding by VHH domains is mediated by three complementarity-determining regions (CDRs): CDR1, CDR2, and CDR3.
Two years after the discovery of camelid heavy-chain-only antibodies, it was reported that sharks and other cartilaginous fish also produced heavy-chain-only antibodies called Ig new antigen receptors (IgNARs). IgNARs are composed of two identical heavy chains, each comprising five constant domains (CNAR1 – 5) and a variable vNAR domain responsible for antigen recognition. Antigen binding by vNAR domains is mediated by CDR1 and CDR3, as well as two small additional HV loops (HV2 and HV4). Additionally, vNARs belong to the Ig superfamily and accordingly, it has a ß-sandwich fold consisting of only eight strands.
Both VHHs and vNARs share several characteristics such as high stability and solubility, longer than average CDR3 loops, and the presence of non-canonical disulfide linkages sculpting the binding site.
While VHH domains have attracted great interest as biological drugs and proven to be successful in clinical trials, the engineering of vNAR domains for biomedical applications is at an early stage. Despite this, with a molecular mass of ~ 12 kDa, the vNAR domain is the smallest antibody-like antigen-binding domain in the animal kingdom known to date and it is abundantly clear that they present a singular molecular framework that can be exploited to develop reagents for scientific research, disease diagnosis, and/or therapeutic intervention:
The vNAR of IgNAR from several species of shark, including nurse shark and wobbegong shark, is a valid alternative to camelids-derived products. Unfortunately, the large size of shark species together with the impossibility of captivity, slow maturity, aggressive temper, and unpredictable behavior are the major issues hampering the success of vNAR-derived products.
To address these issues, we have established and validated a nanobody discovery platform using a local small shark species, the whitespotted bamboo shark, commonly kept as a home aquarium fish. This species is known for its docility and small size, allowing for large-scale husbandry and cost-effective production of superior nanobodies. In contrast, our competitors use larger shark species, such as nurse sharks, which are more challenging to work with. By utilizing the whitespotted bamboo shark, we have achieved a reduction in production costs.
At Jotbody, we are dedicated to the discovery of nanobodies. Our platform offers two distinct approaches to generating nanobodies: immunized and naïve libraries.
Here’s how each approach works:
Our immunized library approach involves generating a nanobody library from camelids or sharks that have been immunized with the target antigen. This approach is particularly useful when the antigen is well characterized and when a strong immune response is expected. With our immunization program in Australia, we optimize the protocol to ensure a robust and specific immune response. We then use high-throughput screening methods to identify nanobodies with the desired binding properties.
Our naïve library approach utilizes a diverse collection of nanobodies generated from an animal without prior exposure to the antigen of interest. This approach is particularly useful when the antigen is not well characterized or when the target is difficult to generate antibodies against. We use state-of-the-art screening techniques to identify nanobodies with high affinity and specificity toward the target antigen.
Our team of experts has extensive experience in immunized and naïve library approaches, and we work closely with our clients to determine which approach best suits their specific needs. We also offer customized solutions to meet the unique requirements of each project, including antibody engineering and optimization, as well as downstream applications such as imaging, diagnostics, and therapeutics.
Whether you are looking to generate nanobodies using immunized or naïve libraries or require customized solutions for your specific project, our team is here to help.
Our typical workflow for the discovery of nanobodies using an immunized library involves several key stages:
The first step involves the immunization of camelids or sharks with the antigen of interest. We work closely with our clients to design an optimized immunization protocol, tailored to their specific antigen of interest. We carefully select the most appropriate animal species and immunization schedule to ensure a robust and specific immune response.
Once the animal has been immunized, we collect peripheral blood mononuclear cells (PBMCs) from the animal. PBMCs are isolated from whole blood using standard laboratory techniques and contain the immune cells, including B cells, which produce the antibodies of interest.
Next, we use the PBMCs collected from the animal to generate a library of nanobodies. We use state-of-the-art technologies and techniques to construct a highly diverse and representative library of single-domain antibodies. This involves isolating the mRNA from the immune cells and converting it to cDNA, which is then amplified using PCR. The amplified DNA is then cloned into a vector to create a library of nanobodies.
Once the library has been constructed, we employ high-throughput screening techniques to identify nanobodies with high affinity and specificity toward the target antigen. We use advanced methods such as phage display to rapidly screen the library for binders and perform multiple rounds of screening and optimization to further enhance the binding properties of the selected nanobodies.
Once the desired nanobodies have been identified, we produce them in large quantities using recombinant protein expression systems. This involves cloning the selected antibodies into expression vectors and transfecting them into host cells. The antibodies are then purified to high levels of purity using standard laboratory techniques.
Finally, we validate the selected nanobodies for their binding specificity and functionality. We use a range of methods, including ELISA, Western blotting, and functional assays, to confirm the binding properties of the antibodies. We work closely with our clients to ensure that the selected antibodies meet their specific needs and requirements.
Throughout the workflow, our team of experts works closely with our clients to ensure their specific needs and requirements are met. We provide regular updates on the progress of the project and are committed to delivering high-quality and reliable results in a timely manner.
Phase no. | Items | Timeline | Deliverables |
I | Antigen preparation | TBD | QC reports |
II | Animal immunization | ~10 weeks (Camelids)16~24 weeks (Sharks) | Sera, PBMC, antibody titer |
III | Immune phage display library construction | ~3 weeks | Immune library construction, library quality evaluation |
IV | Antigen-specific binder screening | ~3 weeks | Enriched antigen-specific phage after 3~4 rounds of panning |
V | Binder identification and validation | ~3 weeks | Sequences of positive clones, purified binders, bioactivity validation |
VI | Data analysis and report writing | ~1 week | Project final report |
Total | 5~6 months (Camelids) 6.5~8.5 months (Sharks) |
The typical workflow for the discovery of nanobodies using a naïve library can be broken down into the following steps:
The naïve library is then screened against the target antigen of interest using a process called bio-panning. This involves incubating the library with the target antigen and then washing away any non-specific binders. The remaining binders are eluted and amplified, and the process is repeated for several rounds to enrich high-affinity binders.
Once the desired nanobodies have been identified, we produce them in large quantities using recombinant protein expression systems. This involves cloning the selected antibodies into expression vectors and transfecting them into host cells. The antibodies are then purified to high levels of purity using standard laboratory techniques.
Finally, we validate the selected nanobodies for their binding specificity and functionality. We use a range of methods, including ELISA, Western blotting, and functional assays, to confirm the binding properties of the antibodies. We work closely with our clients to ensure that the selected antibodies meet their specific needs and requirements.
Overall, the discovery of nanobodies using a naïve library is a powerful technique for generating highly specific and stable binders with a wide range of potential applications.
Phase No, | Items | Timeline | Deliverables |
I | Antigen preparation | TBD | QC reports |
II | Antigen-specific binder screening | ~3 weeks | Enriched antigen-specific phage after 3~4 rounds of panning |
III | Binder identification and validation | ~3 weeks | Sequences of positive clones, purified binders, bioactivity validation |
IV | Data analysis and report writing | ~1 week | Project final report |
Total | 1.5~2 months for naïve nanobody discovery |
Advancements in Extracellular Vesicles for Drug Delivery
Functionalization of extracellular vesicles for gene therapy: new method for EV nucleic acid loading and surface modification